Table 1.
Study demographic and clinical data.
| HC | MDD | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pooled sample | iTBS rTMS Arm | 10 Hz rTMS Arm | ||||||||
| All MDD | Non-responder | Responder | Non-responder | Responder | Non-responder | Responder | ||||
| N | 70 | 266 | 137 | 129 | 68 | 65 | 69 | 64 | ||
| Mean age (SD; range) | 36 (14;18–66) | 43 (12; 18–64) | 42 (11; 18–62) | 45 (11; 21–64) | 43 (9; 19–59) | 43 (11; 21–63) | 40 (13; 18–62) | 47 (11; 22–64) | ||
| Sex (f/m) | 37/33 | 163/103 | 82/55 | 81/48 | 45/23 | 41/24 | 37/32 | 40/24 | ||
| Mean years of education (SD) | – | 17 (3) | 17 (4) | 16 (3) | 17 (4) | 17 (3) | 16 (4) | 16 (3) | ||
| Mean baseline HSRD-17 score (SD) | – | 23 (4) | 23 (4) | 24 (4) | 23 (4) | 24 (4) | 23 (5) | 24 (4) | ||
| Mean %HSRD-17 change from baseline (SD)a | – | −43% (32) | −16% (21) | −71% (11) | −14% (22) | −73% (10) | −18% (20) | −70% (11) | ||
|
Receiving pharmacotherapy during treatment N (% of total) Benzodiazepine |
0 | 87 (33) | 52 (38) | 35 (27) | 28 (41) | 19 (29) | 24 (35) | 16 (25) | ||
| Antidepressant | 0 | 211 (79) | 110 (80) | 101 (78) | 53 (78) | 47 (72) | 55 (80) | 56 (88) | ||
aRepresents the % change in HSRD-17 score from baseline to the final rTMS treatment.